Evogene Ltd. (EVGN)

Market Cap	32.62M
Revenue (ttm)	2.42M
Net Income (ttm)	-22.84M
Shares Out	52.24M
EPS (ttm)	-0.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,231
Open	0.630
Previous Close	0.630
Day's Range	0.604 - 0.640
52-Week Range	0.550 - 1.440
Beta	0.98
Analysts	Strong Buy
Price Target	4.50 (+620.58%)
Earnings Date	Nov 16, 2023

About EVGN

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, su...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 137
• Stock Exchange: NASDAQ
• Ticker Symbol: EVGN

Financial Performance

In 2022, Evogene's revenue was $1.68 million, an increase of 80.11% compared to the previous year's $930,000. Losses were -$26.64 million, -4.16% less than in 2021.

Analyst Forecast

According to 2 analysts, the average rating for EVGN stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 620.58% from the latest price.

Price Target

$4.5

(620.58% upside)

Analyst Consensus: Strong Buy